Dorsey Wright & Associates Invests $1.38 Million in Genmab A/S Sponsored ADR $GMAB

Dorsey Wright & Associates bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 44,837 shares of the company’s stock, valued at approximately $1,381,000.

A number of other institutional investors and hedge funds also recently modified their holdings of GMAB. Corient Private Wealth LLC lifted its holdings in shares of Genmab A/S by 10.9% during the fourth quarter. Corient Private Wealth LLC now owns 17,469 shares of the company’s stock valued at $535,000 after purchasing an additional 1,724 shares during the last quarter. Braeburn Wealth Management LLC acquired a new position in shares of Genmab A/S in the 4th quarter valued at $1,084,000. Vident Advisory LLC increased its stake in Genmab A/S by 11.4% in the 4th quarter. Vident Advisory LLC now owns 39,707 shares of the company’s stock worth $1,223,000 after purchasing an additional 4,060 shares in the last quarter. XTX Topco Ltd increased its stake in Genmab A/S by 16.5% in the 4th quarter. XTX Topco Ltd now owns 35,597 shares of the company’s stock worth $1,096,000 after purchasing an additional 5,051 shares in the last quarter. Finally, Superstring Capital Management LP acquired a new stake in Genmab A/S during the 4th quarter worth about $898,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

GMAB stock opened at $25.27 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The stock has a market cap of $15.76 billion, a P/E ratio of 19.14, a P/E/G ratio of 1.51 and a beta of 0.85. The firm has a 50 day simple moving average of $26.56 and a 200 day simple moving average of $29.03. Genmab A/S Sponsored ADR has a 52 week low of $20.23 and a 52 week high of $35.43.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright dropped their target price on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Wells Fargo & Company began coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective on the stock. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Truist Financial began coverage on Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.